A5076913575- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV, Drug Use, Sexual Risk
- HIV-related health complications and treatments
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Opioid Use Disorder Treatment
- Respiratory viral infections research
- Hepatitis B Virus Studies
- Sex work and related issues
- Immune Cell Function and Interaction
- Pain Management and Opioid Use
- Tuberculosis Research and Epidemiology
- Immunodeficiency and Autoimmune Disorders
- Pneumonia and Respiratory Infections
- Experimental Learning in Engineering
- Influenza Virus Research Studies
- Substance Abuse Treatment and Outcomes
- Liver Disease Diagnosis and Treatment
- Virology and Viral Diseases
- Musculoskeletal Disorders and Rehabilitation
Denver Public Health
2016-2025
University of Colorado Denver
2016-2025
Denver Health Medical Center
2016-2025
Health and Hospital Corporation
2014-2025
Public Health Institute
2022-2025
University of Colorado Hospital
2025
University of Colorado Anschutz Medical Campus
2005-2024
Forth Valley Royal Hospital
2023
National Center for Nanoscience and Technology
2023
Royal Society of Chemistry
2022
BackgroundLY-CoV555, a neutralizing monoclonal antibody, has been associated with decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients coronavirus disease 2019 (Covid-19). Data are needed on effect this antibody patients who hospitalized Covid-19.MethodsIn platform trial therapeutic agents, we randomly assigned had Covid-19 without end-organ failure 1:1 ratio to receive either LY-CoV555 matching placebo. In addition, all received...
Tenofovir (TFV) disoproxil fumarate (TDF)±emtricitabine (FTC) are widely used for HIV treatment and chemoprophylaxis, but variable adherence may lead to suboptimal responses. Methods that quantify would allow interventions improve prevention outcomes. Our objective was characterize the pharmacokinetics of TFV-diphosphate (TFV-DP) FTC-triphosphate (FTC-TP) in red blood cells (RBCs) peripheral mononuclear (PBMCs); extend RBC analysis dried spots (DBSs); model how RBC/DBS monitoring could...
ABSTRACT Studies of daily emtricitabine-tenofovir disoproxil fumarate (FTC-TDF) for HIV preexposure prophylaxis (PrEP) in men who have sex with (MSM) modeled intracellular tenofovir-diphosphate (TFV-DP) dried blood spots (DBS) to assess adherence and corresponding PrEP outcomes. We conducted a prospective, randomized, crossover pharmacokinetic study TFV-DP DBS during 33%, 67%, or 100% dosing under directly observed therapy (DOT). Participants were assigned two 12-week regimens, separated by...
BackgroundSince the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might benefit for patients with infection, but definitive data do not exist. We aimed to evaluate safety efficacy of hIVIG in a randomised controlled trial.MethodsThis randomised, double-blind, placebo-controlled trial was planned 45 hospitals Argentina, Australia, Denmark, Greece, Mexico, Spain,...
Human immunodeficiency virus (HIV)–infected individuals exhibit residual inflammation regardless of virologic suppression. We evaluated whether suboptimal adherence to combination antiretroviral therapy (cART) is associated with greater than optimal adherence, despite Longitudinal self-reported cART data and serum concentrations 24 biomarkers immune activation were measured at the same study visit in HIV RNA–suppressed (<50 copies/mL) HIV-infected men Multicenter AIDS Cohort Study from 1998...
In a randomized, placebo-controlled, clinical trial, bamlanivimab, SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients COVID-19 based on an early futility assessment.
Objectives: To investigate the occurrence of differential adherence to components combination antiretroviral therapy and assess its predictors association with virological failure medication resistance. Design: A secondary analysis prospective clinical trial data. Methods: The Flexible Initial Retrovirus Suppressive Therapies study (Community Programs for Clinical Research on AIDS 058) was a randomized comparing non-nucleoside reverse transcriptase inhibitor (NNRTI) versus protease (PI)...
Background. We assessed factors associated with antiretroviral therapy (ART) adherence, including specific ART medications.
Objective: To determine if immediate compared to deferred initiation of antiretroviral therapy (ART) in healthy persons living with HIV had a more favorable impact on health-related quality life (QOL), or self-assessed physical, mental, and overall health status. Design: QOL was measured the Strategic Timing Antiretroviral Therapy study, which randomized ART-naive CD4+ cell counts above 500 cells/μl from 35 countries versus ART. Methods: At baseline, months 4 12, then annually, participants...
The pharmacokinetics (PK) of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP), the active anabolites tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) in blood, genital, rectal compartments was determined HIV-positive seronegative adults who undertook a 60-day intensive PK study daily TDF/FTC (plus efavirenz HIV positives). Lymphocyte cell sorting, sampling occurred once per subject, at staggered visits. Among 19 (3 female) 21 (10 adults, TFV-DP peripheral blood...
Abstract Background Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility human immunodeficiency virus (HIV) treatment remains unknown. Methods DBS for TFV-DP were collected up to 3 times over 48 weeks persons living with HIV (PLWH) who receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline was compared using t-tests or analyses variance; generalized estimating equations used...
Strategies to increase pre-exposure prophylaxis (PrEP) uptake are needed. We hypothesized that same-day PrEP initiation in a sexually transmitted diseases (STD) clinic would be acceptable, feasible, and safe, individuals engage ongoing care.Individuals aged ≥ 18 years were evaluated for PrEP. Exclusion criteria HIV, history of renal dysfunction or chronic hepatitis B infection, pregnancy, indications HIV post-exposure prophylaxis, positive screen acute symptoms. One hundred received free...
ABSTRACT New objective measures of antiretroviral adherence are needed. We determined if emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS) can be used as a marker recent dosing with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC). The half-life FTC-TP was estimated DBS samples obtained from an intensive pharmacokinetic (PK) study coformulated TDF-FTC HIV-negative and HIV-infected participants. concordance quantifiable (TFV)/FTC plasma evaluated by utilizing paired...
To evaluate opportunities for earlier human immunodeficiency virus (HIV) diagnosis within a comprehensive public health care system.Retrospective review of newly diagnosed HIV-infected patients between September 2001 and December 2003.One hundred twenty 348 (34%) had medical our system in the 3 years before diagnosis. One five 120 (88%) at least 1 prior encounter emergency department or urgent center, whereas just 12 (10%) HIV diagnoses were made these 2 sites. Only 33 (28%) previously...